Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
1.
Vasa ; 48(5): 443-449, 2019 Aug.
Article in English | MEDLINE | ID: mdl-30969161

ABSTRACT

Deep vein thromboses lead to post thrombotic syndrome in up to 50% of patients, which entails significant morbidity and socioeconomic costs. Endovascular treatment of iliofemoral deep vein thrombosis aims to reduce the development and the severity of post thrombotic syndrome. This case series of four cases demonstrates that acute and chronic thrombotic stenoses or occlusions can be safely managed by ultrasound guided endovascular treatment minimizing the number of interventions, bleeding risk and radiation exposure.


Subject(s)
Postthrombotic Syndrome , Venous Thrombosis , Humans , Iliac Vein , Thrombectomy , Thrombolytic Therapy , Ultrasonography
2.
Curr Drug Targets ; 18(7): 863-873, 2017.
Article in English | MEDLINE | ID: mdl-28034277

ABSTRACT

A complex network of different cytokines and chemokines modulates atherosclerosis, a chronic inflammatory disease. Interleukin-17A (IL-17A) is expressed by different leukocyte subsets such as CD4+IL-17+ T cells (Th17), γδ T cells, natural killer cells, natural killer T cells, and neutrophils. IL-17A plays an important role in host defense and is involved in the pathology of different autoimmune and inflammatory diseases. Recent studies demonstrate an association of IL-17A with atherosclerosis. IL-17A seems to have primarily pro-inflammatory effects in atherogenesis, although there are partially controversial results in the literature. In the murine system, several studies indicate a pro-atherogenic role of IL-17A mediated by increased migration of leukocytes (especially macrophages) into atherosclerotic lesions, increased expression of pro-inflammatory cytokines and chemokines as well as plaque destabilizing matrix-metalloproteinases using Apoe-/- and LDLr-/- mice. In contrast, three studies show atheroprotective effects of IL-17A mediated by downregulation of aortic VCAM-1 expression on endothelial cells and increased collagen production by vascular smooth muscle cells (VSMCs) in LDLr-/- mice. In humans, expression of IL-17A was associated with increased inflammation and plaque vulnerability in human atherosclerotic lesions. Moreover, IL-17A induced a pro-inflammatory, pro-thrombotic, plaque-destabilizing, and cell-attracting response of the inflammatory milieu of human plaque tissue samples. Notably, a recently published study challenged these findings by showing a worse outcome of patients with acute myocardial infarction with low serum levels of IL-17A. In the following review, we will focus on the recent progress of functional studies of IL-17A in atherosclerosis and will try to collect explanations for the controversial data.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Atherosclerosis/pathology , Interleukin-17/metabolism , Animals , Anti-Inflammatory Agents/pharmacology , Atherosclerosis/drug therapy , Atherosclerosis/immunology , Cell Movement , Disease Models, Animal , Humans , Leukocytes/cytology , Mice , Molecular Targeted Therapy , T-Lymphocytes/immunology
3.
JACC Cardiovasc Imaging ; 9(3): 255-66, 2016 Mar.
Article in English | MEDLINE | ID: mdl-26965729

ABSTRACT

OBJECTIVES: This study sought to evaluate myocardial perfusion reserve index (MPRI) and diastolic strain rate, both assessed by cardiac magnetic resonance (CMR) as a noninvasive tool for the detection of microvasculopathy. BACKGROUND: Long-term survival of cardiac allograft recipients is limited primarily by cancer and cardiac allograft vasculopathy (CAV). Besides epicardial CAV, diagnosed by coronary angiography, stenotic microvasculopathy was found to be an additional independent risk factor for survival after heart transplantation. METHODS: Sixty-three consecutive heart transplant recipients who underwent CMR, coronary angiography, and myocardial biopsy were enrolled. Stenotic vasculopathy in microvessels was considered in myocardial biopsies by immunohistochemistry and CAV was graded during coronary angiography according to International Society of Heart and Lung Transplantation criteria. In addition, by CMR microvasculopathy was assessed by myocardial perfusion reserve during pharmacologic hyperemia with adenosine and strain-encoded magnetic resonance using a modified spatial modulation of magnetization tagging pulse sequence in all patients. RESULTS: Decreasing MPRI and diastolic strain rates were observed in patients with decreasing microvessel luminal radius to wall thickness ratio and decreasing capillary density (r = 0.45 and r = 0.61 for MPRI and r = 0.50 and r = 0.38 for diastolic strain rate, respectively; p < 0.005 for all). Using multivariable analysis, both MPRI and diastolic strain rate were robust predictors of stenotic microvasculopathy, independent of age, organ age, and CAV by International Society of Heart and Lung Transplantation criteria (hazard ratio: 0.07, p = 0.006 for MPRI; hazard ratio: 0.91, p = 0.002 for diastolic strain rate). Patients without stenotic microvasculopathy in the presence of no or mild CAV (n = 36) exhibited significantly higher median survival free of events, compared with patients with stenotic microvasculopathy in the presence of no or mild CAV (n = 18; p = 0.04 by log rank). CONCLUSIONS: CMR represents a valuable noninvasive diagnostic tool, which may be used for the early detection of transplant microvasculopathy before the manifestation of CAV during surveillance coronary angiographic procedures.


Subject(s)
Coronary Artery Disease/diagnostic imaging , Coronary Circulation , Coronary Vessels/diagnostic imaging , Heart Transplantation/adverse effects , Magnetic Resonance Imaging , Microcirculation , Myocardial Contraction , Myocardial Perfusion Imaging/methods , Adenosine/administration & dosage , Adult , Aged , Allografts , Biopsy , Coronary Angiography , Coronary Artery Disease/etiology , Coronary Artery Disease/physiopathology , Coronary Vessels/physiopathology , Coronary Vessels/surgery , Disease-Free Survival , Female , Humans , Hyperemia/physiopathology , Male , Middle Aged , Predictive Value of Tests , Stress, Mechanical , Treatment Outcome , Vasodilator Agents/administration & dosage
4.
Drug Des Devel Ther ; 8: 2359-71, 2014.
Article in English | MEDLINE | ID: mdl-25473269

ABSTRACT

Despite advances in the pharmacologic and interventional treatment of coronary artery disease, atherosclerosis remains the leading cause of death worldwide. Atherosclerosis is a chronic inflammatory disease, and elevated expression of CCL19 and CCL21 has been observed in ruptured lesions of coronary arteries of patients with myocardial infarction and carotid plaques of patients with ischemic symptoms, as well as in plasma of coronary artery disease patients. However, the exact role of CCL19 and CCL21 in atherosclerosis remains unknown. In order to identify CCL19 and CCL21 as a novel therapeutic target, we performed bone marrow transplantation as an immunomodulatory treatment concept. Bone marrow of plt/plt mice (lacking CCL19 and CCL21-Ser) was transplanted into atherogenic Ldlr(-/-) mice. The study demonstrated a significantly increased inflammatory cellular infiltration into the lesions of plt/plt/Ldlr(-/-) mice versus controls. Although the level of chemoattraction was increased, messenger ribonucleic acid and protein levels in thoracic aorta and serum of several proinflammatory cytokines (TNFα, IFNγ, IL-6, IL-12, and IL-17) were significantly reduced in plt/plt/Ldlr(-/-) versus control mice. Increased influx, accompanied by reduced activation of leukocytes in atherosclerotic lesion, was accompanied by increased plaque stability but unchanged lesion development. In conclusion, modulation of the chemokines CCL19 and CCL21 represents a potent immunoregulatory treatment approach, and thus represents a novel therapeutic target to stabilize atherosclerotic lesions.


Subject(s)
Atherosclerosis/metabolism , Atherosclerosis/pathology , Chemokine CCL19/metabolism , Chemokine CCL21/metabolism , Inflammation/metabolism , Animals , Chemokine CCL19/deficiency , Chemokine CCL21/deficiency , Inflammation/pathology , Male , Mice , Mice, Inbred C57BL , Mice, Knockout
5.
J Immunol ; 193(9): 4344-55, 2014 Nov 01.
Article in English | MEDLINE | ID: mdl-25261478

ABSTRACT

Atherosclerosis is a chronic inflammatory disease. Lesion progression is primarily mediated by cells of the monocyte/macrophage lineage. IL-17A is a proinflammatory cytokine, which modulates immune cell trafficking and is involved inflammation in (auto)immune and infectious diseases. But the role of IL-17A still remains controversial. In the current study, we investigated effects of IL-17A on advanced murine and human atherosclerosis, the common disease phenotype in clinical care. The 26-wk-old apolipoprotein E-deficient mice were fed a standard chow diet and treated either with IL-17A mAb (n = 15) or irrelevant Ig (n = 10) for 16 wk. Furthermore, essential mechanisms of IL-17A in atherogenesis were studied in vitro. Inhibition of IL-17A markedly prevented atherosclerotic lesion progression (p = 0.001) by reducing inflammatory burden and cellular infiltration (p = 0.01) and improved lesion stability (p = 0.01). In vitro experiments showed that IL-17A plays a role in chemoattractance, monocyte adhesion, and sensitization of APCs toward pathogen-derived TLR4 ligands. Also, IL-17A induced a unique transcriptome pattern in monocyte-derived macrophages distinct from known macrophage types. Stimulation of human carotid plaque tissue ex vivo with IL-17A induced a proinflammatory milieu and upregulation of molecules expressed by the IL-17A-induced macrophage subtype. In this study, we show that functional blockade of IL-17A prevents atherosclerotic lesion progression and induces plaque stabilization in advanced lesions in apolipoprotein E-deficient mice. The underlying mechanisms involve reduced inflammation and distinct effects of IL-17A on monocyte/macrophage lineage. In addition, translational experiments underline the relevance for the human system.


Subject(s)
Atherosclerosis/immunology , Atherosclerosis/metabolism , Interleukin-17/metabolism , Macrophages/metabolism , Monocytes/metabolism , Animals , Antibodies, Monoclonal/pharmacology , Aorta/drug effects , Aorta/immunology , Aorta/metabolism , Aorta/pathology , Apolipoproteins E/deficiency , Apolipoproteins E/genetics , Atherosclerosis/drug therapy , Atherosclerosis/genetics , Atherosclerosis/pathology , CD4-Positive T-Lymphocytes/immunology , CD4-Positive T-Lymphocytes/metabolism , Cell Adhesion/drug effects , Cell Differentiation , Cluster Analysis , Coculture Techniques , Cytokines/genetics , Cytokines/metabolism , Disease Models, Animal , Disease Progression , Foam Cells/pathology , Gene Expression Profiling , Humans , Inflammation Mediators/metabolism , Interleukin-17/antagonists & inhibitors , Interleukin-17/pharmacology , Lipid Metabolism , Macrophages/cytology , Macrophages/drug effects , Macrophages/immunology , Male , Mice , Mice, Knockout , Monocytes/cytology , Monocytes/drug effects , Monocytes/immunology , Plaque, Atherosclerotic/drug therapy , Plaque, Atherosclerotic/immunology , Plaque, Atherosclerotic/metabolism , Plaque, Atherosclerotic/pathology , Platelet Adhesiveness/drug effects , Transcriptome
6.
Front Physiol ; 5: 296, 2014.
Article in English | MEDLINE | ID: mdl-25152736

ABSTRACT

The presence of adventitial inflammation in correlation with atherosclerotic lesions has been recognized for decades. In the last years, several studies have investigated the relevance and impact of adventitial inflammation on atherogenesis. In the abdominal aorta of elderly Apoe(-/-) mice, adventitial inflammatory structures were characterized as organized ectopic lymphoid tissue, and therefore termed adventitial tertiary lymphoid organs (ATLOs). These ATLOs possess similarities in development, structure and function to secondary lymphoid organs. A crosstalk between intimal atherosclerotic lesions and ATLOs has been suggested, and several studies could demonstrate a potential role for medial vascular smooth muscle cells in this process. We here review the development, phenotypic characteristics, and function of ATLOs in atherosclerosis. Furthermore, we discuss the possible role of medial vascular smooth muscle cells and their interaction between plaque and ATLOs.

7.
J Vis Exp ; (87)2014 May 06.
Article in English | MEDLINE | ID: mdl-24836700

ABSTRACT

Atherosclerosis is a chronic inflammatory disease of the vasculature. There are various methods to study the inflammatory compound in atherosclerotic lesions. Mouse models are an important tool to investigate inflammatory processes in atherogenesis, but these models suffer from the phenotypic and functional differences between the murine and human immune system. In vitro cell experiments are used to specifically evaluate cell type-dependent changes caused by a substance of interest, but culture-dependent variations and the inability to analyze the influence of specific molecules in the context of the inflammatory compound in atherosclerotic lesions limit the impact of the results. In addition, measuring levels of a molecule of interest in human blood helps to further investigate its clinical relevance, but this represents systemic and not local inflammation. Therefore, we here describe a plaque culture model to study human atherosclerotic lesion biology ex vivo. In short, fresh plaques are obtained from patients undergoing endarterectomy or coronary artery bypass grafting and stored in RPMI medium on ice until usage. The specimens are cut into small pieces followed by random distribution into a 48-well plate, containing RPMI medium in addition to a substance of interest such as cytokines or chemokines alone or in combination for defined periods of time. After incubation, the plaque pieces can be shock frozen for mRNA isolation, embedded in Paraffin or OCT for immunohistochemistry staining or smashed and lysed for western blotting. Furthermore, cells may be isolated from the plaque for flow cytometry analysis. In addition, supernatants can be collected for protein measurement by ELISA. In conclusion, the presented ex vivo model opens the possibility to further study inflammatory lesional biology, which may result in identification of novel disease mechanisms and therapeutic targets.


Subject(s)
Cell Culture Techniques/methods , Plaque, Atherosclerotic/pathology , Carotid Arteries/pathology , Coronary Vessels/pathology , Flow Cytometry , Humans
8.
Transpl Int ; 26(3): 267-72, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23252662

ABSTRACT

Following heart transplantation, cardiac biomarkers remain elevated for several weeks eventually as a result of membrane leakage of the donor organ. We now test the predictive power of blood levels of troponin T (TNT) measured by the new hsTNT assay (Roche Diagnostics, Roche Diagnostics, Mannheim, Germany) early after heart transplantation. TNT was determined in 141 cardiac allograft recipients and 40 controls. Our findings demonstrate that patients who died within the first year after transplantation had significantly higher median hsTNT serum levels 6 weeks after transplantation (156 ng/l ± 203 vs. 29 ng/l ± 21, P = 0.0002). Using ROC analysis, a serum hsTNT concentration of 33.55 ng/l 6 weeks after transplantation was found to be the best cutoff to predict death at 1 year (HR 0.16, 95%CI:0.05-0.46, P = 0.001) with a sensitivity of 90.91% and a specificity of 70.97%. In addition, survival at 5 years (HR 0.15, 95% CI 0.06-0.35, P < 0.0001) was significantly better among patients below that cutoff value. In multivariate analysis, hsTNT serum level 6 weeks after transplantation emerged as an independent predictor for first-year mortality (hsTNT-HR 0.90, 95% CI: 0.81-1.00, P = 0.03). Cardiac troponin T concentrations early after transplantation as measured with a highly sensitive assay represent a strong and independent risk predictor of death after heart transplantation.


Subject(s)
Heart Transplantation/mortality , Heart Transplantation/methods , Survivors/statistics & numerical data , Troponin T/blood , Biomarkers/blood , Case-Control Studies , Female , Germany , Graft Rejection , Graft Survival , Heart Failure/diagnosis , Heart Failure/surgery , Heart Transplantation/adverse effects , Humans , Kaplan-Meier Estimate , Male , Middle Aged , Multivariate Analysis , Postoperative Care/methods , Predictive Value of Tests , Prognosis , Proportional Hazards Models , Retrospective Studies , Risk Assessment , Sensitivity and Specificity , Statistics, Nonparametric , Survival Analysis , Transplantation, Homologous , Treatment Outcome
9.
Clin Neurophysiol ; 122(5): 942-50, 2011 May.
Article in English | MEDLINE | ID: mdl-20843737

ABSTRACT

OBJECTIVE: In a randomized controlled trial, we could demonstrate clinical efficacy of neurofeedback (NF) training for children with ADHD (Gevensleben et al., 2009a). The present investigation aimed at learning more about the neuronal mechanisms of NF training. METHODS: Children with ADHD either completed a NF training or a computerized attention skills training (ratio 3:2). NF training consisted of one block of theta/beta training and one block of slow cortical potential (SCP) training, each comprising 18 training units. At three times (pre-training, between the two training blocks and at post-training), event-related potentials (ERP) were recorded during the Attention Network Test. ERP analysis focused on the P3, reflecting inter alia attentional resources for stimulus evaluation, and the contingent negative variation (CNV), primarily related to cognitive preparation. RESULTS: After NF training, an increase of the CNV in cue trials could be observed, which was specific for the SCP training. A larger pre-training CNV was associated with a larger reduction of ADHD symptomatology for SCP training. CONCLUSIONS: CNV effects reflect neuronal circuits underlying resource allocation during cognitive preparation. These distinct ERP effects are closely related to a successful NF training in children with ADHD. In future studies, neurophysiological recordings could help to optimize and individualize NF training. SIGNIFICANCE: The findings contribute to a better understanding of the mechanisms underlying NF training in children with ADHD.


Subject(s)
Attention Deficit Disorder with Hyperactivity/therapy , Brain/physiopathology , Neurofeedback , Analysis of Variance , Attention/physiology , Attention Deficit Disorder with Hyperactivity/physiopathology , Child , Contingent Negative Variation , Electroencephalography , Evoked Potentials/physiology , Female , Humans , Male , Neurons/physiology , Regression Analysis , Treatment Outcome
10.
J ECT ; 27(1): 48-50, 2011 Mar.
Article in English | MEDLINE | ID: mdl-20351571

ABSTRACT

Seizure induction is a rare, but serious adverse effect of the otherwise very safe method of transcranial magnetic stimulation (TMS). There are only very few single case reports concerning seizure in single-pulse TMS. All of these reports describe individuals with neurological disorders or epileptogenic medication. To our knowledge, we are the first to describe a healthy subject who developed symptoms of a seizure after single-pulse TMS during motor threshold estimation. This case report provides evidence that single-pulse TMS may provoke a seizure even in the absence of neurological risk factors. Differential diagnoses of a classic neurological seizure, that is, convulsive syncope and psychogenic seizure, are discussed. Neurogenic seizure after TMS and convulsive syncope are the most probable hypotheses, although clear specification of this singular incident remains impossible. Therefore, to minimize the risk for such rare adverse effects, existing and new suggestions are combined to provide reasonable precautions to be taken before and during TMS application.


Subject(s)
Seizures/etiology , Transcranial Magnetic Stimulation/adverse effects , Adult , Humans , Male
11.
Basic Res Cardiol ; 106(1): 125-34, 2011 Jan.
Article in English | MEDLINE | ID: mdl-21116822

ABSTRACT

A chronic (auto)immune response is the critical mechanism in atherosclerosis. Interleukin-17A is a pivotal effector cytokine, which modulates immune cell trafficking and initiates inflammation in (auto)immune and infectious diseases. However, expression of IL-17A in the context of human atherosclerosis has hardly been explored. Carotid artery plaques were collected from 79 patients undergoing endarterectomy. Patients were grouped according to their symptomatic status (TIA, stroke), plaque morphology and medication. Quantitative RT-PCR was used to analyze tissue inflammation and immunohistochemistry to assess cellular source of IL-17A expression and lesion morphology. Carotid plaques from patients with ischemic symptoms were characterized by a highly activated inflammatory milieu including accumulation of T cells (p = 0.04) and expression of IL-6 and VCAM1 (p = 0.02, 0.01). Expression of IL-17A and its positive regulators IL-21 and IL-23 was present in atherosclerotic lesions, significantly upregulated in atheromas of symptomatic patients (p = 0.005, 0.004, 0.03), and expression of IL-17A and IL-21 showed a strong correlation (p = 0.002, r = 0.52). The cellular sources of lesional IL-17A expression are T cells, macrophages, B cells and plasma cells. Vulnerable/ruptured (complicated) plaques were significantly associated with IL-17A expression levels (p = 0.003). In addition, IL-17A showed a marked negative correlation with the potent anti-inflammatory/atheroprotective cytokine IL-10 (p = 0.0006, r = -0.46). Furthermore, treatment with a HMG-CoA reductase inhibitor or acetylsalicylic acid showed reduced levels of IL-21, IL-23 and VCAM1 (all p < 0.05), but did not influence IL-17A. The association of IL-17A with ischemic symptoms and vulnerable plaque characteristics suggests that the pro-inflammatory cytokine IL-17A may contribute to atherosclerosis und plaque instability.


Subject(s)
Atherosclerosis/metabolism , Carotid Arteries/metabolism , Interleukin-17/metabolism , Plaque, Atherosclerotic/metabolism , Aged , Aged, 80 and over , Atherosclerosis/drug therapy , Atherosclerosis/pathology , Carotid Arteries/pathology , Female , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Ischemia/metabolism , Male , Osteopontin/metabolism , Plaque, Atherosclerotic/drug therapy , Plaque, Atherosclerotic/pathology
12.
Neurosci Lett ; 482(2): 172-6, 2010 Sep 27.
Article in English | MEDLINE | ID: mdl-20643186

ABSTRACT

The objective of the study was to investigate neuronal processing during the encoding, retention and retrieval phases of a serial visual working memory task. Particularly, we were interested in how these phases are affected by working memory load and how processing is modulated by methylphenidate. Healthy adults were asked to memorize the order of four, five or six pictures under methylphenidate (20mg) and under placebo while brain electrical activity was recorded. On the performance level, the number of correct responses decreased with increasing working memory load. Concerning brain electrical activity, in the encoding phase P3 amplitudes increased at midline electrodes with increasing memory load while load had no effect in the retention and retrieval phase. Medication neither influenced performance nor the different processing stages significantly. Our data provide evidence that during the encoding phase more attentional resources are allocated in trials with higher load as reflected by larger P3 amplitudes.


Subject(s)
Adrenergic Uptake Inhibitors/pharmacology , Dopamine Uptake Inhibitors/pharmacology , Evoked Potentials, Visual/drug effects , Memory, Short-Term/drug effects , Methylphenidate/pharmacology , Serial Learning/drug effects , Visual Perception/drug effects , Adult , Brain/drug effects , Brain/physiology , Electroencephalography , Female , Humans , Male , Mental Recall/drug effects , Retention, Psychology/drug effects
13.
J Immunol ; 183(12): 8167-75, 2009 Dec 15.
Article in English | MEDLINE | ID: mdl-20007582

ABSTRACT

The importance of an (auto)immune response in atherogenesis is becoming increasingly well understood. IL-17A-expressing T cells modulate immune cell trafficking, initiating inflammation and cytokine production in (auto)immune diseases. In human carotid artery plaques, we previously showed the presence of IL-17A-producing T cells and IL-23; however, IL-17A effects on atherogenesis have not been studied. Aortic root sections from 8-wk-old apolipoprotein E-deficient mice fed a standard chow diet were examined after 12 wk for lesion area, plaque composition, cellular infiltration, cytokine expression, and apoptosis. The treatment group (n = 15) received anti-IL-17A Ab and the controls (n = 10) received irrelevant Abs. Inhibition of IL-17A markedly reduced atherosclerotic lesion area (p < 0.001), maximal stenosis (p < 0.001), and vulnerability of the lesion. IL-17A mAb-treated mice showed reduced cellular infiltration, down-regulation of activation markers on endothelium and immune cells (e.g., VCAM-1), and reduced cytokine/chemokine secretion (e.g., IL6, TNFalpha, CCL5). To investigate possible mechanisms, different atherogenic cell types (e.g., macrophages, dendritic cells, HUVECs, vascular smooth muscle cells) were stimulated with IL-17A in addition to TNF-alpha, IFN-gamma, or LPS to induce cellular activation or apoptosis in vitro. Stimulation with IL-17A induced proinflammatory changes in several atherogenic cell types and apoptotic cell death in murine cells. Functional blockade of IL-17A reduces atherosclerotic lesion development and decreases plaque vulnerability, cellular infiltration, and tissue activation in apolipoprotein E-deficient mice. The present data support a pathogenic role of IL-17A in the development of atherosclerosis by way of its widespread proinflammatory and proapoptotic effects on atherogenic cells.


Subject(s)
Apolipoproteins E/deficiency , Atherosclerosis/immunology , Atherosclerosis/pathology , Interleukin-17/antagonists & inhibitors , Interleukin-17/physiology , Animals , Antibodies, Blocking/administration & dosage , Antibodies, Monoclonal/administration & dosage , Apolipoproteins E/genetics , Apoptosis Regulatory Proteins/antagonists & inhibitors , Apoptosis Regulatory Proteins/immunology , Apoptosis Regulatory Proteins/physiology , Atherosclerosis/prevention & control , Cells, Cultured , Disease Models, Animal , Female , Inflammation Mediators/antagonists & inhibitors , Inflammation Mediators/immunology , Inflammation Mediators/physiology , Interleukin-17/immunology , Mice , Mice, Inbred C57BL , Mice, Knockout
14.
Int J Psychophysiol ; 74(2): 149-57, 2009 Nov.
Article in English | MEDLINE | ID: mdl-19712709

ABSTRACT

In a randomized controlled trial, neurofeedback (NF) training was found to be superior to a computerised attention skills training concerning the reduction of ADHD symptomatology (Gevensleben et al., 2009). The aims of this investigation were to assess the impact of different NF protocols (theta/beta training and training of slow cortical potentials, SCPs) on the resting EEG and the association between distinct EEG measures and behavioral improvements. In 72 (of initially 102) children with ADHD, aged 8-12, EEG changes after either a NF training (n=46) or the control training (n=26) could be studied. The combined NF training consisted of one block of theta/beta training and one block of SCP training, each block comprising 18 units of 50 minutes (balanced order). Spontaneous EEG was recorded in a two-minute resting condition before the start of the training, between the two training blocks and after the end of the training. Activity in the different EEG frequency bands was analyzed. In contrast to the control condition, the combined NF training was accompanied by a reduction of theta activity. Protocol-specific EEG changes (theta/beta training: decrease of posterior-midline theta activity; SCP training: increase of central-midline alpha activity) were associated with improvements in the German ADHD rating scale. Related EEG-based predictors were obtained. Thus, differential EEG patterns for theta/beta and SCP training provide further evidence that distinct neuronal mechanisms may contribute to similar behavioral improvements in children with ADHD.


Subject(s)
Attention Deficit Disorder with Hyperactivity/physiopathology , Attention Deficit Disorder with Hyperactivity/rehabilitation , Biofeedback, Psychology/methods , Cerebral Cortex/physiopathology , Contingent Negative Variation/physiology , Attention/physiology , Brain Mapping , Child , Electroencephalography/methods , Female , Humans , Male , Motor Skills/physiology , Outcome Assessment, Health Care , Psychiatric Status Rating Scales , Psychometrics , Regression Analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...